Colorectal cancer is silently becoming a leading killer among younger adults, and the recent death of 48-year-old actor James Van Der Beek has thrust this alarming trend into the spotlight. But here's where it gets controversial: while overall cancer death rates for those under 50 have dropped by 44% since 1990, colorectal cancer has bucked this trend, emerging as the top cancer killer in this age group after decades of steady increases. This raises a critical question: are we doing enough to protect younger generations?
Colorectal cancer, which originates in the colon or rectum, has sparked intense debate over screening guidelines. Currently, both federal recommendations and the American Cancer Society advise that average-risk individuals begin screening at age 45 with a colonoscopy every 10 years or a stool test every one to three years. Insurance coverage hinges on these guidelines, but this is the part most people miss: the recommended age was only lowered from 50 to 45 in 2021, and not everyone in the medical community agrees with this change.
Rebecca Siegel, senior scientific director at the American Cancer Society, notes that when the age was lowered, “there was a lot of pushback... Even today, not everyone is convinced.” Developing these guidelines is a complex balancing act, weighing the benefits of early detection against risks, resource limitations, and even the inconvenience of missing work. For instance, the risk of colorectal cancer more than doubles from 21 per 100,000 people (ages 40-44) to 47 per 100,000 (ages 45-49), yet only 20% of eligible 44- to 49-year-olds are up to date on screening.
Should we lower the screening age even further? Van Karlyle Morris, a colorectal cancer expert at MD Anderson Center, believes this is worth discussing: “The fact that trends do not suggest colorectal cancer rates in young people are dropping certainly opens the door for conversations around policy change.” However, Dr. Andrew Chan of Mass General Brigham cautions that while rates are rising among younger people, overall incidence remains low, and resources for screening are already stretched thin.
For those with a family or personal history of colorectal cancer or polyps, starting screening before 45 is non-negotiable. Siegel emphasizes, “People need to talk to their families. Even a non-cancerous polyp at age 40 in a relative means you should start screening earlier.”
Symptoms like abdominal pain, rectal bleeding, persistent diarrhea, or iron deficiency anemia should never be ignored. Van Der Beek’s own experience—noticing changes in bowel movements at 46, initially dismissed as coffee-related—led to a Stage 3 diagnosis. Early detection is key, but here’s a thought-provoking question: with noninvasive stool and blood tests available, why isn’t screening more accessible and affordable for younger adults?
While colonoscopy remains the gold standard, its cost without insurance ranges from $1,250 to over $4,000. At-home tests like Cologuard and Shield offer alternatives, but their accuracy varies, especially for detecting precancerous polyps.
Beyond screening, lifestyle changes can significantly reduce risk. Rising obesity, sedentary lifestyles, ultraprocessed diets, and shifts in gut health are all suspected culprits in the surge of young-onset colorectal cancer. Chan stresses, “Screening is important, but I don’t want us to ignore those other factors.”
So, what’s your take? Should screening start even earlier than 45? Are we doing enough to address the lifestyle factors driving this trend? Let’s keep the conversation going—your perspective could save lives.
